What to know first
Answer-first notes for searchers, readers, and clinician conversations.
What GLP-1 medicines do
GLP-1 receptor agonists and related incretin medicines affect appetite, glucose handling, gastric emptying, and satiety signaling. The consumer shorthand is usually 'weight-loss shots,' but the clinical story is broader and more nuanced than the nickname.
Semaglutide vs. tirzepatide
Semaglutide and tirzepatide both have randomized obesity-trial evidence showing larger average weight reduction than placebo in specific study populations. STEP 1 studied once-weekly semaglutide 2.4 mg plus lifestyle intervention for 68 weeks; SURMOUNT-1 studied tirzepatide doses for 72 weeks. Those are not interchangeable trials, so separate placebo-controlled results should not be rewritten as a personal head-to-head forecast.
What results are realistic
Published trial averages describe groups, not individual predictions. They also depend on trial design, dose, adherence, lifestyle support, baseline health, discontinuation handling, and follow-up duration. A useful guide shows source-limited numbers with caveats rather than promising a specific personal outcome.
Safety and compounding boundaries
The current Wegovy and Zepbound labels include boxed-warning language about thyroid C-cell tumors, contraindications involving personal or family history of medullary thyroid carcinoma or MEN 2, and additional warnings and adverse-reaction language that should be checked product by product.
What GLP-1 medicines do
GLP-1 receptor agonists and related incretin medicines affect appetite, glucose handling, gastric emptying, and satiety signaling. The consumer shorthand is usually 'weight-loss shots,' but the clinical story is broader and more nuanced than the nickname.
Approval status matters. Wegovy's current DailyMed label is the label anchor for semaglutide weight-management claims on this hub, while Zepbound's current DailyMed label is the label anchor for tirzepatide claims. Other products, formulations, compounded versions, and investigational medicines can have different indications, warnings, evidence, and quality controls.
- Compare the exact product, formulation, and indication — not just the ingredient name.
- Separate peer-reviewed trial averages from social-media transformation stories.
- Use this guide as a question generator for a licensed clinician, not as start, stop, switch, or dosing guidance.
Semaglutide vs. tirzepatide
Semaglutide and tirzepatide both have randomized obesity-trial evidence showing larger average weight reduction than placebo in specific study populations. STEP 1 studied once-weekly semaglutide 2.4 mg plus lifestyle intervention for 68 weeks; SURMOUNT-1 studied tirzepatide doses for 72 weeks. Those are not interchangeable trials, so separate placebo-controlled results should not be rewritten as a personal head-to-head forecast.
The safer comparison is evidence quality, approved indication, label warnings, side-effect tolerance, access, coverage, monitoring, and whether a long-term plan can be sustained. Avoid broad claims that one medicine is automatically better, safer, or right for every reader.
What results are realistic
Published trial averages describe groups, not individual predictions. They also depend on trial design, dose, adherence, lifestyle support, baseline health, discontinuation handling, and follow-up duration. A useful guide shows source-limited numbers with caveats rather than promising a specific personal outcome.
For semaglutide, STEP 1 reported greater mean weight reduction at 68 weeks with semaglutide 2.4 mg plus lifestyle intervention than placebo plus lifestyle intervention in adults without diabetes. For tirzepatide, SURMOUNT-1 reported dose-dependent mean weight reduction versus placebo at 72 weeks in adults with obesity or overweight without diabetes. Both findings should stay attached to their trial populations and endpoints.
Safety and compounding boundaries
The current Wegovy and Zepbound labels include boxed-warning language about thyroid C-cell tumors, contraindications involving personal or family history of medullary thyroid carcinoma or MEN 2, and additional warnings and adverse-reaction language that should be checked product by product.
FDA's unapproved GLP-1 page warns that unapproved versions do not go through FDA review for safety, effectiveness, or quality before marketing. Trial evidence for approved branded products should not be transferred to compounded, salt-form, research-use, or gray-market products.
What to discuss before starting or changing therapy
A good GLP-1 conversation includes indication fit, contraindications, current medications, pregnancy planning, gallbladder or pancreas history, severe GI disease, eating-disorder history, side-effect management, nutrition support, access, and a maintenance or discontinuation plan.
- Bring label and side-effect questions to a clinician rather than treating online summaries as instructions.
- Ask what monitoring and follow-up should look like for your health history.
- Plan for maintenance, nutrition, resistance training, and coverage changes before the first refill problem.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.